(Q43691230)

English

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

scientific article published on 26 August 2013

Statements

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study (English)
Philip J Johnson
Shukui Qin
Joong-Won Park
Ronnie T P Poon
Jean-Luc Raoul
Philip A Philip
Chih-Hung Hsu
Tsung-Hui Hu
Jeong Heo
Jianming Xu
Ligong Lu
Yee Chao
Eveline Boucher
Kwang-Hyub Han
Seung-Woon Paik
Jorge Robles-Aviña
Lunan Yan
Dmitry Komov
Thomas Decaens
Won-Young Tak
Long-Bin Jeng
David Liu
Rana Ezzeddine
Ian Walters
Ann-Lii Cheng
26 August 2013
3517-3524

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit